GENMAB AS SP.ADR/1/10DK 1 - Asset Resilience Ratio

Latest as of December 2025: 0.00%

GENMAB AS SP.ADR/1/10DK 1 (GE91) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

€12.87 Billion

≈ $15.05 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how GENMAB AS SP.ADR/1/10DK 1's Asset Resilience Ratio has changed over time. Check GE91 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down GENMAB AS SP.ADR/1/10DK 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GE91 market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€0.00	0%
Total Liquid Assets	€0.00	0.00%

Asset Resilience Insights

Limited Liquidity: GENMAB AS SP.ADR/1/10DK 1 maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

GENMAB AS SP.ADR/1/10DK 1 Industry Peers by Asset Resilience Ratio

Compare GENMAB AS SP.ADR/1/10DK 1's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Genfit S.A. PA:GNFT	Biotechnology	64.01%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	22.98%
Altimmune Inc NASDAQ:ALT	Biotechnology	82.06%
Clarity Pharmaceuticals Ltd AU:CU6	Biotechnology	73.99%
Jiangsu GDK Biotechnology Co Ltd SHG:688670	Biotechnology	9.82%

Annual Asset Resilience Ratio for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for GENMAB AS SP.ADR/1/10DK 1.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.00%	€0.00 ≈ $0.00	€12.87 Billion ≈ $15.05 Billion	--
2024-12-31	24.54%	€1.57 Billion ≈ $1.83 Billion	€6.39 Billion ≈ $7.47 Billion	-13.06pp
2023-12-31	37.60%	€1.97 Billion ≈ $2.30 Billion	€5.24 Billion ≈ $6.13 Billion	-3.67pp
2022-12-31	41.27%	€1.79 Billion ≈ $2.09 Billion	€4.33 Billion ≈ $5.07 Billion	-0.88pp
2021-12-31	42.15%	€1.58 Billion ≈ $1.85 Billion	€3.75 Billion ≈ $4.38 Billion	--

pp = percentage points

About GENMAB AS SP.ADR/1/10DK 1

F:GE91 Germany Biotechnology

Market Cap

$17.14 Billion

€14.66 Billion EUR

Market Cap Rank

#1624 Global

#351 in Germany

Share Price

€23.80

Change (1 day)

+3.48%

52-Week Range

€17.00 - €29.80

All Time High

€44.40